RxDoctor Payments Data

Sandeep Sharma, MD

Internal Medicine · Rockville, MDNPI 1194734376

Payments from drug & device makers

$2,026in general payments, 2019–2025

Across 37 payments — averaging $54.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$958
  • Acadia Pharmaceuticals Inc$312
  • Kerecis Limited$252
  • Bard Peripheral Vascular, Inc.$123
  • Neurocrine Biosciences, Inc.$105
  • Cardiovascular Systems Inc.$94
  • plus $181 from 7 others

What the payments were for

  • Travel & lodging$43521%
  • Food & beverage$1,59179%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,026 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$336,276
Medicare patients
291
Services billed
3,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban724$294,696
XareltoRivaroxaban221$75,062
JardianceEmpagliflozin125$51,310
RexultiBrexpiprazole34$41,931
JanuviaSitagliptin Phosphate85$33,838
ProcritEpoetin Alfa83$27,415
EntrestoSacubitril/Valsartan82$26,847
MyrbetriqMirabegron61$24,723
Atorvastatin Calcium1,397$23,995
TradjentaLinagliptin48$19,298
RetacritEpoetin Alfa-Epbx52$18,934
Memantine Hcl384$18,717
FarxigaDapagliflozin Propanediol51$14,566
Quetiapine Fumarate514$12,969
Mirtazapine461$12,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Procrit$26$102,477304 claims
AbbVieRestasis$14$10,47217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →